Most Read Articles
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
6 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
15 Mar 2019
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
4 days ago
Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.

Abatacept vs TNFi reduces cardiovascular risk in RA patients

14 Sep 2018

Initiation of abatacept (ABA) vs tumour necrosis factor inhibitors (TNFi) leads to a 20-percent reduction in risk of cardiovascular disease (CVD) in a large cohort of insured patients with rheumatoid arthritis (RA), a US study has shown.

Of the 6,102 propensity score (PS)-matched pairs of ABA and TNFi initiators from Medicare and 6,934 pairs from MarketScan, 35.3 percent in the former and 14.0 percent in the latter had baseline CVD. In the overall ABA vs TNFi group, the hazard ratio (HR) for composite CVD was 0.67 (95 percent CI, 0.55–0.81) in Medicare and 1.08 (0.83–1.41) in MarketScan (combined HR, 0.79; 0.67–0.92).

The HRs among patients with baseline CVD were 0.71 (0.55–0.92) and 1.02 (0.68–1.51) in Medicare and MarketScan, respectively (combined HR, 0.79; 0.64–0.98).

“While this observational study is subject to potential residual confounding, our results were consistent in patients with baseline CVD,” the authors said.

To assess the cardiovascular safety of ABA vs TNFi in RA patients with and without underlying CVD, the authors identified RA patients who initiated ABA or TNFi using data from two large US insurance claims databases: Medicare (2008–2013) and Truven MarketScan (2006–2015).

Stratified by baseline CVD, ABA initiators were PS-matched to TNFi initiators to control for >60 covariates. The authors used Cox proportional hazards regression to estimate HR for a composite endpoint of CVD including myocardial infarction, stroke/transient ischaemic stroke or coronary revascularization in the PS-matched cohorts. An inverse variance-weighted fixed-effects model was used to combine HR from two databases.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
6 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
15 Mar 2019
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
4 days ago
Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.